Products Utlising Licensed Virax Co-X-GeneTM Tech
In March 2007 Transgene (Eurolist Paris: FR0005175080) executed a Licence Agreement (the "Transgene Sub-licence") with the Company for access to Co-X-GeneTM technology for use in two of Transgene's immunotherapeutic products:
• TG4001 - a treatment for pathologies relating to human papilloma virus (HPV) infection; and
• TG4010 - a treatment for non-small cell lung cancer (NSCLC).